Welcome!

News Feed Item

Brazilian Pharmaceutical Market 2014-2024

 

NEW YORK, Jan. 6, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Brazilian Pharmaceutical Market 2014-2024
http://www.reportlinker.com/p01937118/Brazilian-Pharmaceutical-Market-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication


Report Details

Drug selling in Brazil - this new analysis shows you trends, opportunities, and revenues

Do you want to assess the future of pharmaceuticals in Brazil? See what lies ahead, then. Visiongain's new report gives you revenue predictions, helping your work. There you discover financial results, trends, opportunities, and sales forecasts.

So you see what's possible for that trade. Get data to 2024 for the drugs industry operating there. You find business analysis, trends, prospects, and potential revenues.

Read on to explore Brazilian drug sales and see what they could be worth in future.


Trends and outlooks for that developing country - find how you can benefit

Our study concludes that - from 2014 - patients, healthcare providers and pharma companies will benefit from progress in Brazil. You discover where, how, and why.

There you find trading predictions from 2013 to 2024 at overall national and submarket levels. You hear where the money lies. Also save time. See how you can help your research, analyses, and decisions. That way you could gain more influence and recognition.

Forecasts and other data to help you find the most lucrative possibilities

To support our forecasting, our work shows you historical data, recent results, growth rates, and market shares. There you investigate developments and potentials, finding what they mean and their values. You also get 61 tables and 47 charts. So avoid falling behind.

Information on medical commerce in Brazil just got easier to find. And the following sections show you what our investigation gives.

Potentials of medicines in Brazil - national trade forecasting overall and by segment

What're the secrets of that market's progress? What's Brazil's potential? Our study gives you feel for that emerging nation's pharma needs and prospects.

So you discover overall drug revenues there to 2024, with discussions. Our report also shows individual sales predictions - from 2013 to 2024 - for nine submarkets:
• Patented therapies - small-molecule prescription (Rx) agents and biological drugs (biologics)
• Generic pharmaceuticals (generics)
• Over-the-counter (OTC) medicines.

And also for these therapeutic applications, via another market breakdown:
• Central nervous system (CNS) products
• Cardiovascular (CV) diseases treatment
• Alimentary and metabolic disorders therapy
• Cancer treatments (oncology)
• Infectious diseases - anti-infective agents (vaccines and antibiotics)
• Therapies for other illnesses.

How will those sectors expand? Which classes of treatment and therapeutic areas will yield most money? There you assess commercial outlooks, seeing where you can gain.

You also investigate what stimulates and restrains those submarkets.


Issues and events - what affects developers, producers, and sellers of medicines in Brazil?

Our report also discusses forces shaping pharma there from 2013 to 2024, including these:
• Strategies companies and healthcare providers use to serve that country's needs, as well as technologies (inc. R&D) and strategic advantages
• Contributions of domestic and foreign companies, inc. their entry
• Demographic trends and governmental policies, inc. pricing and regulations
• Efforts by regions to improve medical provision, better serving patients
• Brazil's position in Latin American, BRIC nations, and world pharma business.

There you examine political, economic, social, and technological questions, assessing commercial outlooks. Explore what stimulates and restrains drug developers and makers.

You see, then, what affects participants in that industry and you find its potential.

Analysis of top companies and their industry's performance - what results possible?

What happens next? Our work predicts the Brazilian pharma market will reach $41.3bn in 2017 - with fast expansion - and by 2024 contribute strongly to world medical revenues.

You discover what causes that rise. First, the study explains activities of 12 leading domestic companies, in particular, including these firms:
• EMS
• Medley
• Hypermarcas
• Aché
• Eurofarma.

You also assess 17 multinational (big pharma) organisations, inc. these corporations:
• Sanofi
• Novartis
• Roche
• Pfizer
• Merck & Co.

Discover the efforts of specialists too, including firms making biopharmaceuticals.


Developments of leading generics and biosimilar manufacturers

In the report you also review international producers and marketers of generics and biosimilars, including these players targeting Brazil:
• Teva
• Sandoz
• Mylan
• Actavis
• Ranbaxy.

From 2014 great progress in Brazilian medical sales will occur. Pharma industry leaders and specialty operations - esp. manufacturers of generic and biosimilar drugs - stand to profit.


Ways Brazilian Pharmaceutical Market 2014-2024 helps you

In particular, then, our new investigation gives you this knowledge:
• Revenues to 2024 at national level and for 9 submarkets - explore prospects for investments, marketing, and sales
• Analyses of what stimulates and restrains medical enterprises there - assess challenges, strengths, and competition affecting participants' strategies
• Prospects for established competitors, rising companies, and new entrants - analyse portfolios, R&D, approvals, collaborations, strategy, and chances of success.

Information found nowhere else, letting you appraise Brazilian pharma activities

Our new report gives independent analysis. There you receive competitive intelligence found only in our work, finding where the money exists. Explore progress and possibilities.

With that report you're less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find there how you could save time and effort, also benefiting your authority.
1. Executive Summary

1.1 Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods


2. Overview of the Brazil Pharmaceutical Market, 2014-2024

2.1 Market to Continue Strong Performance to 2024
2.2 The Sixth-Largest Economy in the World in 2012
2.2.1 Population Size the Biggest Driver for the Market
2.2.2 Generics Segment Continues to Grow in Importance
2.2.3 CNS Remains the Largest Therapeutic Area in 2012
2.2.4 Three Domestic Companies in Top Six for 2012
2.3 Why the Brazilian Market Matters: Regional and Global Market Context
2.3.1 Brazil Represented 46% of the Latin American Market in 2012
2.3.2 Brazil as Part of the BRIC/'Pharmerging' Markets in 2013

3. Brazilian Healthcare: Commercial Overview, 2014-2024

3.1 ANVISA The Key Institutional Body
3.1.1 Other Important Agencies
3.2 Over 62% Supplement SUS with Private Healthcare
3.2.1 CMED Adjusts Prices Up for 2013
3.2.2 Reimbursement for RENAME Drugs via Farmácia Popular
3.2.3 Private Insurance Market Growing, but Costs for Insurers Rising
3.3 M&A-Led Consolidation Continues in Both Wholesale and Retail Sectors
3.3.1 Celesio-Owned Panpharma Still the Top Distributor
3.3.2 RaiaDrogasil, Brazil Pharma and Other Major Chains Hold 47% of Retail Sector
3.3.3 Marketing Spend in Brazil Approaches $5bn
3.4 A Nation of Contrasts: Healthcare Variations in the Brazilian Regions
3.4.1 Southeast: Over 40% of the National Population, But Over Half of Pharmaceutical Market Revenues
3.4.2 Northeast: Shortest Life-Expectancies and Second-Highest Market Share
3.4.3 South: Smallest Region with Highest Per Capita GDP
3.4.4 MidWest: Landlocked Region with Lowest Population
3.4.5 North: Largest and Poorest Area Represents

<5% of Market>4. Product Mix in the Brazilian Market, 2014-2024

4.1 How Much Ground Will Generics Gain by 2024?
4.2 Patented Pharmaceuticals: Still the Basis of the Brazil Market
4.2.1 PDPs and HTA: Government Attempts to Regulate Costs
4.2.2 The Battle for Biomanufacturing Capabilities
4.2.3 Can BioNovis and Orygen Build on Aché's Biosimilar Advances?
4.2.4 At 55% More Expensive, Can Patented Products Hold Off the Generics Revolution?
4.2.5 Market Forecast for Prescription Pharmaceuticals, 2014-2024
4.3 Generic Pharmaceuticals: Rapid Expansion Since 2000
4.3.1 Pró-Genéricos Anticipate 45% Market Capture
4.3.2 The Issue of Non-Bioequivalent Drugs
4.3.3 Counterfeits: Believed At Least 7% of Brazil's Drug Supply Affected
4.3.4 Generics Opportunity Not Yet Fully Harnessed
4.3.5 Market Forecast for Generic Pharmaceuticals, 2014-2024
4.4 OTC Segment: Still Favoured by Brazilian Consumers
4.4.1 Coming Out From Behind the Counter
4.4.2 Advertising: ABIMIP Lobbies on DTC Restrictions
4.4.3 Vitamins and Minerals Purchased by ~15% of Brazilians
4.4.4 From Analgesics to Erectile Dysfunction Treatments, Consumer Health Treatments Remain Prominent in the Market
4.4.5 Market Forecast for the OTC Segment, 2014-2024


5. Therapeutic Areas in the Brazil Market, 2014-2024

5.1 Oncology to Overtake CNS Diseases by 2024
5.2 The Rise of Non-Communicable Diseases
5.3 CNS Conditions: Disease Burden Comparable to US
5.3.1 Domestic Companies Target OTC and Generic Pain Relief
5.3.2 Foreign Competition in the Analgesics Area
5.3.3 Prevalence of 10%+ Represents Major Opportunity in Antidepressant Space
5.3.4 CNS Conditions: A Therapeutic Area with Unique Relevance to Brazil
5.3.5 Market Forecast for CNS Therapeutic Area 2014-2024
5.4 Cardiovascular Diseases: Brazil's Biggest Killer
5.4.1 Anti-hypertensives: One of the Nation's Key Drugs
5.4.2 Decline of the Statins
5.4.3 Ache and Sanofi Among the Key Players in This Field
5.4.4 The Heart Disease Opportunity over the Next 10 Years
5.4.5 Market Forecast for Cardiovascular Therapeutic Area 2014-2024
5.5 Alimentary/Metabolic Diseases: Affecting More Than a Third of Brazilians
5.5.1 Lack of Diabetes Awareness Still an Issue
5.5.2 Biosimilar Insulins to Play an Important Role
5.5.3 EMS' Generic Esomeprazole an Important Addition
5.5.4 Capturing the Alimentary/Metabolic Disease Opportunity
5.5.5 Market Forecast for Alimentary/Metabolic Therapeutic Area 2014-2024
5.6 Oncology: To Become the Biggest Therapeutic Area?
5.6.1 Breast Cancer Has the Highest Prevalence in Brazil
5.6.2 Biosimilars to Help Widen Medicine Access
5.6.3 Eurofarma, Cristalia and Libbs the Domestic Leaders
5.6.4 Will the Oncology Therapeutic Area Realise its Potential?
5.6.5 Market Forecast for Cancer Treatment 2014-2024
5.7 Infectious Diseases: Brazil Faces Unique Challenges
5.7.1 PPDs to Meet Vaccines Need
5.7.2 Brazil Managing HIV Despite IP Concerns
5.7.3 Chagas Disease and Other Infectious Disease Concerns
5.7.4 Infectious Disease: The Past or the Future for Brazilian Pharma?
5.7.5 Market Forecast for Infectious Disease Treatment, 2014-2024
5.8 Other Therapeutic Areas


6. Domestic Companies in the Brazilian Market, 2014-2024

6.1 EMS Continues to Lead the Field with 8% Market Share
6.2 Purchase of Medley Means Multinationals Still Own Bulk of Market
6.2.1 Domestic Firms Control 70% of Generics Market
6.3 EMS Pharma: First Among Brazilian Generics Firms
6.3.1 Significant R&D, Manufacturing and Sales Capabilities
6.3.2 Targeting Expansion Oversees
6.3.3 Legrand and Germed Key Subsidiaries of EMS
6.4 Medley: Foreign-Owned Generics Leader Maintains 8% Market Share in 2012
6.5 Hypermarcas: Diversified Drugstore Chain
6.5.1 Neo Química Genericos: Third-Ranked in Generics Segment
6.5.2 Other Key Hypermarcas Subsidiaries Include Brainfarma
6.5.3 Hypermarcas Performance in 2012
6.6 Aché: The Major Acquisition Target in Brazil
6.6.1 Cardiovascular Drugs the Main Focus
6.6.2 Ache: Possible M&A?
6.6.3 A Large Domestic Merger an Alternative Possibility?
6.7 Laboratorios Eurofarma: Diversified Leader with Hospital, Generic and Veterinary Business Units
6.7.1 Vigorous Latin American Acquisitions Policy
6.7.2 Strong Presence in Cancer Treatment
6.8 Laboratorio Teuto Brasileiro: Largest Pharmaceutical Complex in Latin America
6.8.1 Melcon Partnership and Other Growth Strategies for Teuto
6.9 Biolab-Sanus Farma: 100+ Products, Four Exclusive
6.9.1 Collaborations with Emcure and Merz
6.10 Laboratório Cristália: R&D Leader
6.10.1 Leader in API Manufacturing
6.10.2 Involved in Nearly Half of All PDP Arrangements
6.11 Libbs Farmacêutica: Key Player in Cancer Treatment
6.11.1 Working on a Biosimilar - Opening New Possibilities
6.12 Uniao Quimica Farmaceutica Nacional: Expanding in Minas Gerais
6.13 Other Domestic Players
6.14 The Major Biosimilar Collaborations
6.14.1 BioNovis: Aiming at Commercialisation by 2015
6.14.2 Orygem Biotecnologia
6.15 Other Potential Sources of Innovation
6.15.1 Fundação Oswaldo Cruz: At the Heart of PDP
6.15.2 ANVISA Reform of Brazilian Patent System


7. Multinational Companies in the Brazilian Market, 2014-2024

7.1 M&A Propels Sanofi into First Position
7.2 Multinational Investment in the Market Continues to Grow
7.3 Sanofi: Medley Purchase Makes French Giant the Outright Leader
7.3.1 Genzyme and Consumer Health the Main Growth Drivers
7.3.2 Generics Sales Stall in 2012
7.3.3 Inventory and 2013 Results
7.4 Novartis: Brazil Now Sixth-Largest Market
7.4.1 Sandoz Sales Grow by 29% in 2012
7.4.2 Pricing and Reimbursement Solutions to Bring Original Drugs to Brazil
7.4.3 Co-operating on Technology Transfer and Other Ideas
7.5 Roche: Double-Digit Brazilian Growth in 2012
7.5.1 Positioned to Tap the Oncology Opportunity
7.5.2 Herceptin, Pricing and Reimbursement
7.6 Merck & Co. - Long-Standing Presence in the Brazilian Market
7.6.1 Gardasil Added to SUS in 2013
7.6.2 ExcelRX JV to Increase Merck's Standing in Brazil
7.7 Pfizer: Targeting Emerging Market Growth via M&A
7.7.1 Portfolio Ranges from Orphan Biologics to Multivitamins
7.7.2 How Will a Pfizer Break-Up Affect Emerging Market Plans?
7.8 Bayer: Brazil Fifth-Largest Market for Diversified Conglomerate
7.8.1 Consumer Health a Major Focus in Brazil
7.9 AstraZeneca: Struggling with Patent Expiries in Brazil
7.9.1 Possible Future Growth Drivers Include Diabetes
7.10 Boehringer Ingelheim: Pain, Cardiovascular and Respiratory Drugs Bolster Strong National Portfolio
7.10.1 Technology Transfer Deal for Sifrol
7.11 Takeda: Entering the Top 10 with Multigrip OTC Acquisition
7.11.1 Nycomed Generics and Original Products Also Key to Strategy
7.12 Merck Serono: Over 6% Consumer Health Growth Forecast
7.13 Other Big-Pharma Competitors
7.13.1 Johnson & Johnson: Focusing on Consumer Health and Commodities
7.13.2 GlaxoSmithKline: Vaccines Technology Transfer Opportunities
7.13.3 Abbvie: Humira to Face Biosimilar Challenge in Brazil?
7.13.3.1 Abbott: Generics and Diagnostics-Led Growth Strategy
7.13.4 Eli Lilly: Patent Expiries Hit Emerging Market Revenues.
7.13.5 Bristol-Myers Squibb: Divesting its Brazilian OTC Portfolio Rights
7.13.6 Baxter: Entering Brazilian Haemophilia Market via Tech Transfer
7.13.7 Amgen Signals Brazilian Intent with Bergamo Acquisition
7.13.8 Other Top Biotechs Enter Brazil
7.13.9 Other Top Japanese Companies Trail Behind Takeda in Brazil
7.14 Will Multinational Generics Leaders Compete in Brazil?
7.14.1 Teva Pharmaceutical Industries: Generics Giant Targets Brazil
7.14.2 Mylan: Agile Acquisition Boosts Latin American Strategy
7.14.3 Actavis: Newly-Merged Player to Challenge in Brazil
7.14.4 Ranbaxy Hands Over to Daiichi, but Other Indian Companies Still in the Hunt in Brazil
7.14.5 Glenmark, Strides and Biocon Looking to Enter Brazil
7.14.6 Valeant: Aggressive M&A Drive Into the Market
7.15 Brazil as Research Destination
7.16 Other Multinational Business in Brazil


8. Qualitative Analysis of the Brazilian Market, 2014-2024

8.1 A Crucial Market for the Pharmaceutical Industry?
8.2 Governmental Regulation Remains an Issue
8.3 Room to Expand in Therapeutic Areas and Geographical Regions
8.4 IP Protection: Doubts, Red Tape and Counterfeiting Remain Issues
8.5 Large and Ageing Population Eager to Buy Medicines
8.6 Improved Biotechnology and Digital Among Government's Goals
8.7 Can Economic Growth Keep Pace With Healthcare Costs?
8.8 Political Environment the Decisive Influence on the Market

9. Conclusions from the Research and Analysis

9.1 Brazil Likely to Outperform Most Other Top 10 Pharma Markets
9.2 Generics to be the Fastest-Growing Segment
9.3 Technology Transfer Crucial to Patented Drugs Market
9.4 Generics and Patented Products: Opportunities for Multinationals
9.5 Anti-cancer Drugs: Biggest Therapeutic and Commercial Opportunity
9.6 Concluding Remarks

List of Tables

Table 1.1 Currency Exchange Rates
Table 2.1 Brazilian Pharmaceutical Market: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 2.2 Brazilian Pharmaceutical Market: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 2.3 Product Mix Breakdown: Revenues ($m), Market Share (%), 2012
Table 2.4 Therapeutic Area Breakdown: Revenues ($m), Market Share (%), 2012
Table 2.5 Leading Companies in the Brazilian Pharma Market: Revenues ($m), Market Shares (%), 2012
Table 2.6 Leading National Markets Worldwide: Revenues ($m), Market Shares (%), 2012
Table 2.7 Leading National Markets in Latin America: Revenues ($m), Market Shares (%), 2012
Table 2.8 Leading National 'Pharmerging' Markets: Revenues ($m), Market Shares (%), 2012
Table 3.1 Members of FenaSaúde, 2013
Table 4.1 Brazilian Pharma Market Breakdown by Product Type: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 4.2 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market Shares (%), 2017
Table 4.3 Brazilian Market Breakdown by Product Type: Revenues ($m), AGR (%), CAGR (%), Market Shares (%) 2018-2024
Table 4.4 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market Shares (%), 2024
Table 4.5 Selected Technology Transfer Agreements in Brazil 1985-2013
Table 4.6 Patented Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 4.7 Patented Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 4.8 Generic Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 4.9 Generic Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 4.10 OTC Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 4.11 OTC Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 5.1 Brazilian Market Breakdown by Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Shares (%) 2012-2017
Table 5.2 Therapeutic Area Breakdown: Revenues ($m), Market Share (%), 2017
Table 5.3 Brazilian Market Breakdown by Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Shares (%) 2018-2024
Table 5.4 Therapeutic Area Breakdown: Revenues ($m), Market Shares (%), 2024
Table 5.5 CNS Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2012-2017
Table 5.6 CNS Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 5.7 Cardiovascular Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 5.8 Cardiovascular Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 5.9 Alimentary/Metabolic Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 5.10 Alimentary/Metabolic Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 5.11 Oncology Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 5.12 Oncology Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 5.13Infectious Disease Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 5.14 Infectious Disease Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 6.1 Leading Domestic Companies in the Brazilian Market: Revenues ($m), Market Shares (%), 2012
Table 6.2 EMS: Overview, 2013
Table 6.3 Medley: Overview, 2013
Table 6.4 Hypermarcas: Overview, 2013
Table 6.5 Aché: Overview, 2013
Table 6.6 Eurofarma: Overview, 2013
Table 6.7 Teuto: Overview, 2013
Table 6.8 Biolab Sanus: Overview, 2013
Table 6.9 Cristália: Overview, 2013
Table 6.10 Libbs: Overview, 2013
Table 6.11 Uniao Quimica: Overview, 2013
Table 7.1 Leading Multinational Companies in the Brazilian Market: Revenues ($m), Market Shares (%), 2012
Table 7.2 Selected Multinational M&A Transactions in Brazilian Market, 2009-2012
Table 7.3 Sanofi: Overview, 2013
Table 7.4 Novartis: Overview, 2013
Table 7.5 Roche: Overview, 2013
Table 7.6 Merck: Overview, 2013
Table 7.7 Pfizer: Overview, 2013
Table 7.8 Bayer: Overview, 2013
Table 7.9 AstraZeneca: Overview, 2013
Table 7.10 Boehringer Ingelheim: Overview, 2013
Table 7.11 Takeda: Overview, 2013
Table 7.12 Merck Serono: Overview, 2013
Table 8.1 Brazilian Pharmaceutical Market: Strengths and Weaknesses, 2013
Table 8.2 Brazilian Pharmaceutical Market: Opportunities and Threats, 2013
Table 8.3 Brazilian Pharmaceutical Market: STEP Analysis, 2013-2024


List of Figures

Figure 2.1 Brazilian Pharmaceutical Market: Revenues ($m), 2012-2024
Figure 2.2 Demographic Breakdown of Brazilian Population by Age, 2013
Figure 2.3 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market Shares (%), 2012
Figure 2.4 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market Shares (%), 2012
Figure 2.5 Leading Companies in the Brazilian Market: Revenues ($m), Market Shares (%), 2012
Figure 2.6 Leading National Markets Worldwide: Revenues ($m), Market Shares (%), 2012
Figure 2.7 Leading National Markets in Latin America: Revenues ($m), Market Shares (%), 2012
Figure 2.8 Leading National 'Pharmerging' Markets: Revenues ($m), 2012
Figure 2.9 BRIC National Markets: Revenues ($m), 2012
Figure 3.1 Public/Private Balance in Healthcare Provision, 2008
Figure 3.2 CMED-Mandated Maximum Drug Price Rises, 2009-2013
Figure 3.3 Distribution (%) of Revenues Among Brazilian Regions, 2012
Figure 4.1 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market Shares (%), 2017
Figure 4.2 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market Shares (%), 2024
Figure 4.3 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), 2012-2024
Figure 4.4 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), 2012, 2017, 2024
Figure 4.5 Biologics in the Brazilian Market: Product Mix Breakdown: Revenues ($m) and Shares (%), 2012
Figure 4.6 Biologics in the Brazilian Market: Product Mix Breakdown: Revenues ($m), 2012, 2017 and 2024
Figure 4.7 Drivers and Restraints for Prescription Pharmaceuticals, 2013
Figure 4.8 Patented Pharmaceuticals: Revenues ($m), 2012-2024
Figure 4.9 Drivers and Restraints for Prescription Pharmaceuticals, 2013
Figure 4.10 Generic Pharmaceuticals: Revenues ($m), 2012-2024
Figure 4.11 Drivers and Restraints for Generic Pharmaceuticals, 2013
Figure 4.12 OTC Pharmaceuticals: Revenues ($m), 2012-2024
Figure 5.1 Therapeutic Area Breakdown: Revenues ($m), Market Shares (%), 2017
Figure 5.2 Therapeutic Area Breakdown: Revenues ($m), Market Shares (%), 2024
Figure 5.3 Therapeutic Area Breakdown: Revenues ($m), 2012-2024
Figure 5.4 Therapeutic Area Breakdown: Revenues ($m), 2012, 2017, 2024
Figure 5.5 Drivers and Restraints for CNS Therapeutic Area, 2013
Figure 5.6 CNS Therapeutic Area: Revenues ($m), 2012-2024
Figure 5.7 Drivers and Restraints for Cardiovascular Therapeutic Area, 2013
Figure 5.8 Cardiovascular Therapeutic Area: Revenues ($m), 2012-2024
Figure 5.9 Drivers and Restraints for Alimentary/Metabolic Therapeutic Area, 2013
Figure 5.10 Alimentary/Metabolic Therapeutic Area: Revenues ($m), 2012-2024
Figure 5.11 Drivers and Restraints for Oncology Therapeutic Area, 2013
Figure 5.12 Oncology Therapeutic Area: Revenues ($m), 2012-2024
Figure 5.13 Drivers and Restraints for Infectious Disease Therapeutic Area, 2013
Figure 5.14 Infectious Disease Therapeutic Area: Revenues ($m), 2012-2024
Figure 6.1 Leading Domestic Companies in the Brazilian Market: Revenues ($m), Market Shares (%), 2012
Table 7.1 Leading Multinational Pharma Companies in the Brazilian Market: Revenues ($m), Market Shares (%), 2012
Figure 9.1 Brazilian Pharmaceutical Market: Revenues ($m), 2012-2017
Figure 9.2 Brazilian Pharmaceutical Market: Revenues ($m), 2018-2024
Figure 9.3 Product Mix: Revenues ($m), 2012-2017
Figure 9.4 Product Mix: Revenues ($m), 2018-2024
Figure 9.5 Top 10 Companies in the Brazilian Pharma Market, 2012
Figure 9.6 Therapeutic Areas: Revenues ($m) in Brazil, 2012-2017
Figure 9.7 Therapeutic Areas: Revenues ($m) in Brazil, 2018-2024

Companies Listed

Abbott Laboratories (including Abbvie)
Achê Laboratórios Farmacêuticos
Actavis
Agência Nacional de Saude Suplementar
Agência Nacional de Vigilância Sanitária (ANVISA)
Agila Specialties
AlfaRio
Alliance Boots
Allianz Health
AMB (Brazilian Medical Association)
American Diabetes Association
American Varian Medical Systems
Amgen
Amil Participações
Antaris Consulting
Arena Pharmaceuticals
Arseus
Associação Brasileira da Indústria de Medicamentos Isentos de Prescrição (ABIMIP)
Associação Brasileira das Redes de Farmácias e Drogarias (ABRAFARMA)
Associação Brasileira de Reabilitação de Coluna
Associacao da Industria Farmaceutica de Pesquisa (InterFarma)
Associação Nacional de Assistencia ao Diabetico (ANAD)
Astellas
AstraZeneca
Athos Pharma
Axis Biotec
Baxter
Bayer
BD
Biocon
Biogen Idec
Biolab Emcure
Biolab-Sanus Farma
Biomm
Bionovis
Biosidus
Biovail Corporation
Boehringer Ingelheim
Boiron
Bradesco Saúde
Brainfarma Industria e Farmaceutica
Brasil Pharma
Brazilian Development Bank (BNDES)
Bristol-Myers Squibb
BTG Pactual
Bunker Industria Farmaceutica
Caixa Seguros
Câmara de Regulação do Mercado de Medicamentos (CMED)
Cannes RJ Participacoes
Castro Marques Group
Celesio
Chemo
Claris Lifesciences
CMED
Comissão Nacional de Incorporação de Tecnologia (CONITEC)
Comitê Técnico Assessor de Imunizações (CTAI)
Conselho Administrativo de Defesa Econômica
Corporacion Infarmasa
CPhI Worldwide
CVS Pharmacy
Daiichi Sankyo
Datamatrix
Delta Instituto Terapeutico
Dimed
Disaq Pharmaceuticals
DM Industria Farmaceutica
Dong-A
DPSP
Drogarias Tamoio
Eisai
Eli Lilly
Emcure
EMS
Eurofarma
Everis
Excel RX
FarmaBrasil group
Farmácia Popular
Farmadacta Informatica
Farmais
Far-Manguinhos
Farmindustria
FDA
Federação Nacional de Saúde Suplementar
Federal Council of Medicine (CFM)
Fiocruz
Food and Drug Administration (US FDA)
Forest Laboratories
GE
Genfar
Genzyme
Germed Pharma
Gilead Sciences
GlaxoSmithKline (GSK)
Glenmark
Golden Cross Assistance
Grünenthal
Grupo Bradesco
Grupo Cimed
Guararapes
Health Canada
Hebron
Hemobrás
Hospital das Clínicas
Hospital Israelita Albert Einstein
Hospital Santa Catarina
Hypermarcas
IMA Laboratories
Indian Council of Medical Research
Infectious Disease Research Institute (IDRI)
Institut Pasteur
Instituto Butantan
Instituto de Estudos de Saúde Suplementar (IESS)
Interagile Propaganda e Promocoes
Intermédica
Itauseg Health
Johnson &?Johnson (J&J)
Kenya Medical Research Institute
Laboratorio Cristália
Laboratório Daudt Oliveira
Laboratório Farmaceutico do Estado de Pernambuco (LAFEPE)
Laboratorio Quimico Farmaceutico Bergamo
Laboratorio Teuto Brasileiro
Laboratorios Gautier
Laboratórios Kendrick
Laboratórios Klinger Do Brasil
Laramara
Legrand
Libbs Farmacêutica
Locafarma Solucoes de Transportes e Logistica
Luper Indústria Farmacêutica
Mais Econômica
Mantecorp Industria Quimica e Farmaceutica
Maritima Seguros
Mayne Pharma
Médecins sans Frontières
Medley
Meizler Biopharma
Melcon
Merck & Co.
Merck Serono
Merz Pharma
Metlife Dental Plans
Minas Gerais State Department of Health
Ministério da Saúde (Ministry of Health, Brazil)
moksha8
Multilab Industria e Comercio de Produtos Farmaceuticos
Mylan
Nature's Plus Farmaceutica
Neo Química
Neuberger Machines
Novartis
Novo Nordisk
Nycomed
Odontoprev Omint Health Services
Oncoprod
Optimer Pharmaceuticals
Orygen Biotecnologia
Oswaldo Cruz Foundation
Otsuka
Pan American Health Organization
Panarello
Panpharma
Pasteur Institute
Pele Nova
Penha
Pfizer
Pharmaceutical Product Development, LLC (PPD)
PharmaPraxis
Porto Seguro
Probiomed
Probiotica
Procter & Gamble
Profarma
Pró-Genéricos
Promovendas Representacoes
Protalix BioTherapeutics
Quesada Farmaceutica
Quintiles
RaiaDrogasil
Ranbaxy
Reckitt Benckiser
Regional Council of Medicine, State of São Paulo
Roche
Rosário
Sabin Vaccine Institute
Sandoz
Sanofi
Sant'Ana
Santa Cruz
Shasun Pharma
Siemens
Sincamesp
Sinclair IS Pharma
Sindusfarma
Sistema Único de Saude (SUS)
Strides Arcolab
SulAmérica
Sun
Supera Farma Laboratorios
Takeda
Telefônica Digital
Tempo Participações
Teva Pharmaceutical industries
TKS Farmaceutica
Torrent
Toshiba
UCB
UERJ
UFMG
UFRJ
Uniao Quimica
UNICAMP
UNIFESP
Unimed Seguros
UnitedHealth
University of São Paulo
Valeant
Varian Medical Systems
Volta
Walgreens
Watson Pharmaceuticals (now Actavis)
Wheaton Brazil
Wockhardt
World Health Organization (WHO)
Zydus Cadila


To order this report: Brazilian Pharmaceutical Market 2014-2024
http://www.reportlinker.com/p01937118/Brazilian-Pharmaceutical-Market-20...



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
Headquartered in Plainsboro, NJ, Synametrics Technologies has provided IT professionals and computer systems developers since 1997. Based on the success of their initial product offerings (WinSQL and DeltaCopy), the company continues to create and hone innovative products that help its customers get more from their computer applications, databases and infrastructure. To date, over one million users around the world have chosen Synametrics solutions to help power their accelerated business or per...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and ...
We are seeing a major migration of enterprises applications to the cloud. As cloud and business use of real time applications accelerate, legacy networks are no longer able to architecturally support cloud adoption and deliver the performance and security required by highly distributed enterprises. These outdated solutions have become more costly and complicated to implement, install, manage, and maintain.SD-WAN offers unlimited capabilities for accessing the benefits of the cloud and Internet. ...
Founded in 2000, Chetu Inc. is a global provider of customized software development solutions and IT staff augmentation services for software technology providers. By providing clients with unparalleled niche technology expertise and industry experience, Chetu has become the premiere long-term, back-end software development partner for start-ups, SMBs, and Fortune 500 companies. Chetu is headquartered in Plantation, Florida, with thirteen offices throughout the U.S. and abroad.
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
DXWorldEXPO LLC announced today that Dez Blanchfield joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Dez is a strategic leader in business and digital transformation with 25 years of experience in the IT and telecommunications industries developing strategies and implementing business initiatives. He has a breadth of expertise spanning technologies such as cloud computing, big data and analytics, cognitive computing, m...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory?
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
HyperConvergence came to market with the objective of being simple, flexible and to help drive down operating expenses. It reduced the footprint by bundling the compute/storage/network into one box. This brought a new set of challenges as the HyperConverged vendors are very focused on their own proprietary building blocks. If you want to scale in a certain way, let's say you identified a need for more storage and want to add a device that is not sold by the HyperConverged vendor, forget about it...
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
One of the biggest challenges with adopting a DevOps mentality is: new applications are easily adapted to cloud-native, microservice-based, or containerized architectures - they can be built for them - but old applications need complex refactoring. On the other hand, these new technologies can require relearning or adapting new, oftentimes more complex, methodologies and tools to be ready for production. In his general session at @DevOpsSummit at 20th Cloud Expo, Chris Brown, Solutions Marketi...
At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.